Sangamo Therapeutics Announces First Quarter 2023 Conference Call and Webcast

Rhea-AI Summary

Sangamo Therapeutics, a genomic medicine company, is set to release its first quarter 2023 financial results after market close on April 26, 2023. A conference call will follow on April 27, 2023 at 8:30 a.m. ET, open to the public for financial and business updates.

Participants can register for the call via a provided link, with options to dial in or use a direct phone connect. A replay will be accessible post-call under the company's 'Events and Presentations' section.

Sangamo is focused on innovative genomic medicines, leveraging proprietary technologies to address unmet medical needs. For more information, visit their website.

Positive

• Scheduled financial results release could attract investor interest.
• The company's focus on genomic medicine aligns with growing industry trends.

Negative

• None.

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its first quarter 2023 financial results after the market closes on Wednesday, April 26, 2023.

The Company will hold a conference call at 8:30 a.m. ET on Thursday, April 27, which will be open to the public. During the conference call, the company will review its financial results and provide business updates.

Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.

A replay will be available following the conference call, accessible under Events and Presentations.

About Sangamo Therapeutics

Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. Using ground-breaking science, including our proprietary zinc finger genome engineering technology and manufacturing expertise, Sangamo aims to create new genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or currently don’t exist. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005760/en/

Investor & Media Inquiries

Louise Wilkie

ir@sangamo.com

media@sangamo.com

Source: Sangamo Therapeutics, Inc.

FAQ

When will Sangamo Therapeutics release its Q1 2023 financial results?

Sangamo Therapeutics will release its Q1 2023 financial results after market close on April 26, 2023.

What time is the Sangamo Therapeutics conference call?

The conference call for Sangamo Therapeutics is scheduled for 8:30 a.m. ET on April 27, 2023.

How can I access the Sangamo Therapeutics conference call?

Participants can register and access the call using the registration link provided in the press release.

What is the focus of Sangamo Therapeutics?

Sangamo Therapeutics is focused on developing genomic medicines using proprietary zinc finger genome engineering technology.